Delora Baptista

Delora Baptista

Auto-generated profile, based on publicly available information

Delora Baptista

University of Minho

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Briefings in Bioinformatics
Verified
Journal Article
Closed access
DBDelora Baptista
Delora Baptista
Pedro G. FerreiraPedro G. Ferreira
Pedro G. Ferreira
Miguel RochaMiguel Rocha
Miguel Rocha
Predicting the sensitivity of tumors to specific anti-cancer treatments is a challenge of paramount importance for precision medicine. Machine learning(ML) algorithms can be trained on high-throughput screening data to develop models that are able to predict the response of cancer cell lines and patients to novel drugs or drug combinations. Deep learning (DL) refers to a distinct class of ML algorithms that have achieved top-level performance in a variety of fields, including drug discovery. These types of models have unique characteristics that may make them more suitable for the complex task of modeling drug response based on both biological and chemical data, but the application of DL to drug response prediction has been unexplored until very recently. The few studies that have been published have shown promising results, and the use of DL for drug response prediction is beginning to attract greater interest from researchers in the field. In this article, we critically review recently published studies that have employed DL methods to predict drug response in cancer cell lines. We also provide a brief description of DL and the main types of architectures that have been used in these studies. Additionally, we present a selection of publicly available drug screening data resources that can be used to develop drug response prediction models. Finally, we also address the limitations of these approaches and provide a discussion on possible paths for further improvement. Contact: mrocha@di.uminho.pt

8 April 2022 in Journal of Integrative Bioinformatics
Verified
Journal Article
Open access
PDF file
DBDelora Baptista
Delora Baptista
JCJoão Correia
João Correia
BPBruno Pereira
Bruno Pereira
Miguel RochaMiguel Rocha
Miguel Rocha
Machine learning (ML) is increasingly being used to guide drug discovery processes. When applying ML approaches to chemical datasets, molecular descriptors and fingerprints are typically used to represent compounds as numerical vectors. However, in recent years, end-to-end deep learning (DL) methods that can learn feature representations directly from line notations or molecular graphs have been proposed as alternatives to using precomputed features. This study set out to investigate which compound representation methods are the most suitable for drug sensitivity prediction in cancer cell lines. Twelve different representations were benchmarked on 5 compound screening datasets, using DeepMol, a new chemoinformatics package developed by our research group, to perform these analyses. The results of this study show that the predictive performance of end-to-end DL models is comparable to, and at times surpasses, that of models trained on molecular fingerprints, even when less training data is available. This study also found that combining several compound representation methods into an ensemble can improve performance. Finally, we show that a post hoc feature attribution method can boost the explainability of the DL models.

23 March 2023 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
DBDelora Baptista
Delora Baptista
Pedro G. FerreiraPedro G. Ferreira
Pedro G. Ferreira
Miguel RochaMiguel Rocha
Miguel Rocha
One of the main obstacles to the successful treatment of cancer is the phenomenon of drug resistance. A common strategy to overcome resistance is the use of combination therapies. However, the space of possibilities is huge and efficient search strategies are required. Machine Learning (ML) can be a useful tool for the discovery of novel, clinically relevant anti-cancer drug combinations. In particular, deep learning (DL) has become a popular choice for modeling drug combination effects. Here, we set out to examine the impact of different methodological choices on the performance of multimodal DL-based drug synergy prediction methods, including the use of different input data types, preprocessing steps and model architectures. Focusing on the NCI ALMANAC dataset, we found that feature selection based on prior biological knowledge has a positive impact—limiting gene expression data to cancer or drug response-specific genes improved performance. Drug features appeared to be more predictive of drug response, with a 41% increase in coefficient of determination (R2) and 26% increase in Spearman correlation relative to a baseline model that used only cell line and drug identifiers. Molecular fingerprint-based drug representations performed slightly better than learned representations—ECFP4 fingerprints increased R2 by 5.3% and Spearman correlation by 2.8% w.r.t the best learned representations. In general, fully connected feature-encoding subnetworks outperformed other architectures. DL outperformed other ML methods by more than 35% (R2) and 14% (Spearman). Additionally, an ensemble combining the top DL and ML models improved performance by about 6.5% (R2) and 4% (Spearman). Using a state-of-the-art interpretability method, we showed that DL models can learn to associate drug and cell line features with drug response in a biologically meaningful way. The strategies explored in this study will help to improve the development of computational methods for the rational design of effective drug combinations for cancer therapy.

22 June 2019
Verified
Book Chapter
Closed access
PDF file
JCJoão Correia
João Correia
TRTiago Resende
Tiago Resende
DBDelora Baptista
Delora Baptista
Miguel RochaMiguel Rocha
Miguel Rocha

17 August 2018
Verified
Book Chapter
Closed access
PDF file
SCSara Cardoso
Sara Cardoso
DBDelora Baptista
Delora Baptista
RSRebeca Santos
Rebeca Santos
Miguel RochaMiguel Rocha
Miguel Rocha

16 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDelora Baptista
Delora Baptista
Pedro G. FerreiraPedro G. Ferreira
Pedro G. Ferreira
Miguel RochaMiguel Rocha
Miguel Rocha
One of the main obstacles to the successful treatment of cancer is the phenomenon of drug resistance. A common strategy to overcome resistance is the use of combination therapies. However, the space of possibilities is huge and efficient search strategies are required. Machine Learning (ML) can be a useful tool for the discovery of novel, clinically relevant anti-cancer drug combinations. In particular, deep learning (DL) has become a popular choice for modeling drug combination effects. Here, we set out to examine the impact of different methodological choices on the performance of multimodal DL-based drug synergy prediction methods, including the use of different input data types, preprocessing steps and model architectures. Focusing on the NCI ALMANAC dataset, we found that feature selection based on prior biological knowledge has a positive impact on performance. Drug features appeared to be more predictive of drug response. Molecular fingerprint-based drug representations performed slightly better than learned representations, and gene expression data of cancer or drug response-specific genes also improved performance. In general, fully connected feature-encoding subnetworks outperformed other architectures, with DL outperforming other ML methods. Using a state-of-the-art interpretability method, we showed that DL models can learn to associate drug and cell line features with drug response in a biologically meaningful way. The strategies explored in this study will help to improve the development of computational methods for the rational design of effective drug combinations for cancer therapy. Author summary Cancer therapies often fail because tumor cells become resistant to treatment. One way to overcome resistance is by treating patients with a combination of two or more drugs. Some combinations may be more effective than when considering individual drug effects, a phenomenon called drug synergy. Computational drug synergy prediction methods can help to identify new, clinically relevant drug combinations. In this study, we developed several deep learning models for drug synergy prediction. We examined the effect of using different types of deep learning architectures, and different ways of representing drugs and cancer cell lines. We explored the use of biological prior knowledge to select relevant cell line features, and also tested data-driven feature reduction methods. We tested both precomputed drug features and deep learning methods that can directly learn features from raw representations of molecules. We also evaluated whether including genomic features, in addition to gene expression data, improves the predictive performance of the models. Through these experiments, we were able to identify strategies that will help guide the development of new deep learning models for drug synergy prediction in the future.